Senti Biosciences Secures Up to $4.55 Million Private Placement Commitment

• Senti Biosciences Holdings entered a November 9, 2026, agreement for up to $4.55 million in common stock purchases by CPIF II-9.
• The investor is affiliated with Celadon Partners SPV 24 Limited; shares will be priced at Nasdaq Listing Rule 5635(d)'s “Minimum Price.”
• Quarterly funding, at the company's option, includes $1.8 million by December 31, 2026, and $1.35 million by March 31, 2027.
• Remaining payments are $500,000 by June 30, 2027; $500,000 by September 30, 2027; and $400,000 by December 31, 2027.
• The private placement relies on Securities Act registration exemptions for a sale to one accredited investor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-072793), on November 10, 2026, and is solely responsible for the information contained therein.